Compare ADMA Biologics Inc (ADMA) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Charles River Laboratories Intl. Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Charles River Laboratories Intl. Inc trades at $221.38 (market cap $11.01B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.2× ADMA Biologics Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | CRL | |
|---|---|---|
Market Cap | $2.13B | $11.01B |
Sector | Health | Health |
52-Week High | $20.38 | $231.43 |
52-Week Low | $7.60 | $145.57 |
Enterprise Value | $2.20B | $13.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
CRL trades at $228.68, down 0.87% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported negative net income of -$144.34M in 2025 despite revenue stability around $4.02B, resulting in a high P/E of 684.85. Recent earnings beats and strategic collaborations, such as with Lilly TuneLab (Business Wire, 2026-06-18), highlight operational strengths amid profitability challenges.
Outlook is mixed: strong analyst support (72% buy ratings) and positive cash flow trends contrast with negative margins and high debt. Key risks include sustained unprofitability and competitive pressures, but institutional confidence and technical momentum suggest potential for recovery if earnings improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
